LANSDOWNE PARTNERS (UK) LLP - SUMMIT THERAPEUTICS PLC ownership

SUMMIT THERAPEUTICS PLC's ticker is SMMT and the CUSIP is 86627R102. A total of 2 filers reported holding SUMMIT THERAPEUTICS PLC in Q3 2023. The put-call ratio across all filers is - and the average weighting 0.0%.

Quarter-by-quarter ownership
LANSDOWNE PARTNERS (UK) LLP ownership history of SUMMIT THERAPEUTICS PLC
ValueSharesWeighting
Q2 2020$7,922,000
-21.0%
2,667,350
-36.9%
0.33%
-40.4%
Q1 2020$10,022,000
+292.3%
4,228,700
+164.8%
0.56%
+704.3%
Q4 2019$2,555,000
-10.6%
1,596,6660.0%0.07%
-9.2%
Q3 2019$2,858,000
+41.5%
1,596,6660.0%0.08%
+52.0%
Q2 2019$2,020,000
-30.9%
1,596,6660.0%0.05%
-23.1%
Q1 2019$2,922,000
+59.2%
1,596,6660.0%0.06%
+140.7%
Q4 2018$1,836,000
-48.2%
1,596,6660.0%0.03%
-27.0%
Q3 2018$3,545,000
-9.4%
1,596,6660.0%0.04%0.0%
Q2 2018$3,912,000
-81.0%
1,596,6660.0%0.04%
-82.7%
Q1 2018$20,597,000
+16.4%
1,596,6660.0%0.21%
+31.3%
Q4 2017$17,691,000
-11.7%
1,596,6660.0%0.16%
-22.0%
Q3 2017$20,038,000
+89.2%
1,596,666
+71.7%
0.21%
+127.2%
Q2 2017$10,593,000
-14.2%
930,0000.0%0.09%
-14.0%
Q1 2017$12,346,000
+55.1%
930,0000.0%0.11%
+50.7%
Q4 2016$7,961,000
-5.6%
930,0000.0%0.07%
-2.7%
Q3 2016$8,430,000
+12.0%
930,0000.0%0.07%
+4.3%
Q2 2016$7,524,000
+18.6%
930,0000.0%0.07%
+40.0%
Q1 2016$6,343,000
-40.7%
930,0000.0%0.05%
-31.5%
Q4 2015$10,695,000
+10.5%
930,0000.0%0.07%
-11.0%
Q3 2015$9,681,000
-1.4%
930,0000.0%0.08%
-2.4%
Q2 2015$9,823,000
-14.8%
930,0000.0%0.08%
-19.2%
Q1 2015$11,523,000930,0000.10%
Other shareholders
SUMMIT THERAPEUTICS PLC shareholders Q3 2023
NameSharesValueWeighting ↓
LANSDOWNE PARTNERS (UK) LLP 2,667,350$7,922,0000.33%
Polar Capital LLP 4,500,000$13,365,0000.12%
Inscription Capital, LLC 17,000$50,0000.03%
BBR PARTNERS, LLC 50,000$149,0000.02%
Checchi Capital Advisers, LLC 20,000$59,0000.01%
Cornerstone Investment Partners, LLC 34,825$103,0000.01%
ACADIAN ASSET MANAGEMENT LLC 49,257$146,0000.00%
Renaissance Technologies 361,112$1,073,0000.00%
HSBC HOLDINGS PLC 150,975$448,0000.00%
CAPTRUST FINANCIAL ADVISORS 11,000$35,0000.00%
View complete list of SUMMIT THERAPEUTICS PLC shareholders